Pharmacy Times
JUNE 6, 2024
By improving health insurance coverage and cost of inhalers, such as out-of-pocket caps, access to care can be increased. Some companies are aiming to improve access by implementing price caps.
STAT
JUNE 6, 2024
The Covid pandemic has been called a “mass-disabling event” since early on — the kind of once-in-a-generation public health crisis that could shape millions of people’s lives forever. But while more people self-identified as disabled since the pandemic began, applications for disability benefits have stayed level, according to data from the Social Security Administration.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 6, 2024
Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.
STAT
JUNE 6, 2024
Federal officials, medical organizations, and reproductive health advocacy groups have expressed outrage in response to STAT’s recent investigation revealing that women with sickle cell disease have felt pressured into sterilizations as recently as 2017 and 2022. Some said they knew of other contemporary instances of tubal ligations with questionable consent — in people with severe disabilities, for instance, or situations in which patients didn’t understand that the procedu
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
JUNE 6, 2024
Restrictive health plan policies are increasingly relying on step therapy for cancer drugs, recent analysis from consulting firm Avalere shows. | Step therapy is embedded within prior auth requirements by health plans, potentially delaying critical access to care for cancer patients. In rare circumstances, patients must go through triple or quadruple step therapy.
STAT
JUNE 6, 2024
No one knows when the next pandemic will sweep across the United States. It could be bird flu , or an as-yet unknown infection. But after living through the Covid-19 pandemic, which claimed more than 1 million American lives, left more than 300,000 children orphaned, and shut down workplaces and schools, U.S. citizens should demand that the nation does better next time.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
JUNE 6, 2024
The Patient Protection and Affordable Care Act , (generally known as the ACA), was signed into law in 2010. It expanded access to affordable, quality health care, and today is helping 45 million people — the highest total on record — be covered by health insurance. The law included long-overdue policy changes to ensure that Americans have access to recommended preventive care, which is critical to avoiding preventable illnesses and the health care spending associated with them.
pharmaphorum
JUNE 6, 2024
Riding high from positive clinical trial results for its oral weight-loss therapy, Structure Therapeutics has filed a public offering that it hopes will raise $476 million
STAT
JUNE 6, 2024
A day after a panel of advisers to the Food and Drug Administration expressed deep concerns about the use of MDMA to help treat post-traumatic stress disorder, companies working to develop other psychedelics said their optimism had not been dimmed — and that the concerns provided a clearer blueprint for what it might take to get such a drug approved.
The Checkup by Singlecare
JUNE 6, 2024
Prednisone is a corticosteroid medication that helps reduce inflammation. This versatile prescription drug is FDA-approved to treat autoimmune and inflammatory conditions such as arthritis, lupus, psoriasis, ulcerative colitis, multiple sclerosis, and endocrine disorders. It can also treat severe allergic reactions. Like any medication, prednisone may cause side effects for some people.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
JUNE 6, 2024
SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group. A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.
Fierce Healthcare
JUNE 6, 2024
Insurers are likely to pay $1.1 billion in Affordable Care Act medical loss ratio rebates in 2024, according to a new analysis. | Insurers are likely to pay $1.1 billion in Affordable Care Act medical loss ratio rebates in 2024, according to a new analysis.
STAT
JUNE 6, 2024
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday: Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug?
Fierce Pharma
JUNE 6, 2024
A new antitrust investigation in Italy has ensnared Novartis, Genentech, Biogen and Samsung Bioepis for allegedly colluding to suppress competition of a Lucentis biosimilar in the country. | Italy's antitrust agency is going after Novartis, Genentech, Biogen and Samsung Bioepis for allegedly working together to delay the launch of a Lucentis biosimilar in Italy.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
JUNE 6, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we discuss how psychedelics companies are responding to the negative ad comm vote on Lykos’ therapy, results of Zepbound in MASH, and the fate of Novovax this fall.
Pharmacy Times
JUNE 6, 2024
FKS518 (Fresenius Kabi) would be indicated for the treatment of osteoporosis in men and women, including glucocorticoid-induced osteoporosis and bone loss due to prostate or breast cancer.
STAT
JUNE 6, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. A new report from the Peterson Health Technology Institute suggests virtual physical therapy services could decrease health care spending for payers that invest in them.
Drug Topics
JUNE 6, 2024
Overdose deaths have decreased for the first time since 2018, but naloxone remains an important tool in fighting the opioid epidemic.
STAT
JUNE 6, 2024
CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to the health care conglomerate anytime soon. A federal appeals court has ruled Bricker, a former high-ranking executive at Cigna, cannot jump to CVS because it would violate her noncompete agreement that she signed while at Cigna. The appeals court’s decision backs up what a district court had previously ruled.
pharmaphorum
JUNE 6, 2024
A man in Mexico has died in what the WHO has said is the first lab-confirmed human infection with the H5N2 strain of bird flu
STAT
JUNE 6, 2024
How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology meeting surpass expectations? We discuss that and more in this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ meeting with an FDA advisory committee.
pharmaphorum
JUNE 6, 2024
Trio of radiopharma financings this week, as Telix files $200m US IPO, ITM raises $202m in a private round, and AstraZeneca invests in CDMO Nucleus.
STAT
JUNE 6, 2024
Top of the morning to you, and a fine one it is, despite the gray skies hovering over the Pharmalot campus again. We are doing our best to maintain sunny spirits, though, because we recall a bit of insight from the Morning Mayor, who taught us that “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.
pharmaphorum
JUNE 6, 2024
Amgen's Uplizna could become the first FDA-approved treatment for rare disease IgG4-RD, after showing efficacy in the phase 3 MITIGATE trial
Fierce Pharma
JUNE 6, 2024
Amid a nuclear medicine boom, France’s Orano Med has chosen the U.S. to establish a manufacturing plant as it progresses on its radiopharma journey. | Orano Med—which is working on targeted alpha therapies for cancer—on Thursday inaugurated its first Alpha Therapy Laboratory (ATLab) in Brownsburg near Indianapolis, Indiana. The site marks the world’s first industrial-scale facility dedicated to production of lead-212-based radioligand therapies, the company said.
European Pharmaceutical Review
JUNE 6, 2024
Final Phase IIb data has confirmed the potential of bulevirtide 10mg in combination with pegylated interferon alfa-2a (PegIFN) as a finite therapy for adults with chronic hepatitis delta virus (HDV), according to Gilead Sciences. The new data is from the MYR204 study which investigated the efficacy and safety of the first-in-class entry inhibitor bulevirtide alone and together with PegIFN, in these patients with compensated chronic HDV infection.
Fierce Pharma
JUNE 6, 2024
AbbVie is one of many drugmakers to plug investments into the antibody-drug conjugate (ADC) field in recent years. | AbbVie announced that Elahere—also known as mirvetuximab soravtansine—met its primary endpoint in the midstage PICCOLO trial, triggering an objective response rate of 51.9%.
Drug Topics
JUNE 6, 2024
HbA1c levels decreased significantly after an average of 154 days in patients who used a continuous glucose monitor.
Fierce Pharma
JUNE 6, 2024
AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. | AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show.
Outsourcing Pharma
JUNE 6, 2024
Yesterday (June 5) CluePoints, providers of established statistical and AI-driven software solutions, and the Food and Drug Administration (FDA) announced an extension to their long-standing collaboration.
Pharmaceutical Technology
JUNE 6, 2024
While the potential for using AI to develop mRNA therapeutics is now a real possibility, accurate and diverse data is needed to make it a reality.
Pharmacy Times
JUNE 6, 2024
Mirikizumab met both co-primary end points and all secondary end points at week 52, according to results presented at Digestive Disease Week in Washington DC.
pharmaphorum
JUNE 6, 2024
CDC recommends doxyPEP as first post-exposure antibiotic for STIs including syphilis, gonorrhoea and chlamydia
Drug Topics
JUNE 6, 2024
Four poster presented at ENDO 2024 examined the current landscape of diabetes.
Expert insights. Personalized for you.
139 
Let's personalize your content